MyoKardia Announces Launch Of Share Patient Registry For Genetic Heart Disease In Collaboration With World-Leading Cardiovascular Patient Care Centers
5/14/2014 8:26:32 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--MyoKardia, Inc., a company pioneering the development of precision therapies for genetic heart disease, today announced the launch of the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical data on individuals with genetic heart disease. The registry was developed in collaboration with investigators from seven world-leading cardiovascular centers and currently contains de-identified data on over 5,800 subjects. SHaRe aims to grow into the world’s most robust database of clinical information on genetic heart disease through relationships with additional clinical investigators and cardiovascular centers of excellence.
Help employers find you! Check out all the jobs and post your resume.
comments powered by